FDA approves first drug to treat agitation associated with dementia due to Alzheimer’s
The U.S. Food and Drug Administration (FDA) on Thursday announced the supplemental approval of Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia due to Alzheimer’s disease. Read More
CRISPR edited rat embryos reveal cause of rare pediatric neurodegenerative disease
Using CRISPR gene editing technology on rat embryos, University of Wisconsin-Madison researchers have revealed the mutation that is responsible for progressive gait abnormalities and other symptoms in human infants and young children with a rare neurodegenerative disease. Read More
Lupus pill moves to clinical trial in humans after success in mice
Scientists at this week’s fall meeting of the American Chemical Society report they have begun phase II clinical trials of an oral pill containing a compound that in mice, not only prevented lupus-like symptoms, but also reversed signs of organ damage caused by the disease and prevented death. Read More
Repetitive DNA linked to cancer formation in study of replication process
Researchers have discovered that noncoding "junk" DNA could potentially contribute to the development of cancer. Repetitive DNA sequences can cause replication to stall, triggering a response that is similar to the one induced by DNA damage, according to a study published July 19 in Nature Communications. Read More
Cardiac mouse model shows role white blood cells play in arrhythmia
Feeding mice a diet lacking in potassium induces ventricular tachycardia, a rapid heartbeat, enabling researchers to study how different white blood cell subclasses influence heart rhythms. Read More
Global consortium creates 'largest' zebrafish genetic atlas to support human disease research
An international consortium of 27 laboratories called DANIO-CODE has created an atlas of genetic data on zebrafish to support research into conditions including cancer, heart disease, and neurodegeneration. Read More
Cell and gene therapy sector remains strong despite challenges: ARM CEO
The cell and gene therapy sector is “quite strong” despite the regulatory, investment, and manufacturing challenges facing the industry, according to Janet Lambert, CEO of the Alliance for Regenerative Medicine (ARM). Lambert spoke with ScienceBoard.net about developments in the industry. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
